Viking Therapeutics, Inc. (NasdaqCM: VKTX)
Health Care · Biotechnology · US
$28.43
-0.28% today · -18.5% 1Y
Viking Therapeutics, Inc. (NasdaqCM: VKTX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $3.33B and employs 65 people.
Over the last twelve months the share price has lost 18.5%, trading between 25.77 and 43.15.
Tweenvest scores Viking Therapeutics, Inc. across four factors: quality 40/100, value 36/100. Its strongest factor is quality.
VKTX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $3.33B
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -4.67
- Dividend yield
- —
- Beta (5Y)
- 0.65
- 52-week high
- $43.15
- 52-week low
- $25.77
- Avg volume (3M)
- —
- Shares outstanding
- 116.65M
- Employees
- 65
- Next earnings
- —
About Viking Therapeutics, Inc.
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.
- ISIN
- US92686J1060
- Founded
- 2012
- Listed since
- Apr 28, 2015
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| IDEAYA Biosciences, Inc.NasdaqGS: IDYA | $3.48B | $36.15 | +0.11% |
| InnoCare Pharma LimitedSEHK: 9969 | $3.46B | HK$12.73 | -6.60% |
| Acadia Pharmaceuticals Inc.NasdaqGS: ACAD | $3.41B | $19.59 | -0.96% |
| Arcutis Biotherapeutics, Inc.NasdaqGS: ARQT | $3.34B | $26.43 | -0.56% |
| Celcuity Inc.NasdaqCM: CELC | $3.32B | $65.81 | -3.14% |
| CareDx, Inc.NasdaqGM: CDNA | $3.29B | $61.73 | -3.05% |
| Denali Therapeutics Inc.NasdaqGS: DNLI | $3.11B | $19.09 | -1.85% |
| Arcus Biosciences, Inc.NYSE: RCUS | $3.11B | $24.53 | +0.49% |
Figures last refreshed Oct 11, 2026.